Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
University of Zurich
First received: August 13, 2010
Last updated: February 28, 2013
Last verified: February 2013
The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.
- Trial with medicinal product
- Trial with immunomodulatory product / biological
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Primary Outcome Measures:
- Immunogenicity [ Time Frame: half a year ]
Geometric mean titer of Varicella zoster virus-specific IgG, VZV-specific T- cells per 106 peripheral mononuclear cells, Frequency of VZV-specific T- cells of total T-cells, CD4+ T-cells in different HIV-positive persons.
- Safety [ Time Frame: half a year ]
Number of Participants with Adverse Events as a Measure of Safety and Tolerability"
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2011 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion criteria: All individuals
- Age >18 years
- Male, or female with negative urine pregnancy test
- VZV-seropositive (serologically documented)
- Agree to use a barrier method of birth control (such as a condom)
- Written informed consent HIV positive individuals on ART (group A1-A3)
- Continuous ART for >3 months before baseline
- No change of ART regimen within 1 month before baseline
- HIV-RNA (value must be <3 months old )<50 copies/ml at last visit
- CD4-count (value must be <3 months old) > 500 cells/µl for group A1, 350-500 cells/µl for group A2 and 250 -349 cells/µl for group A3
- Participation in the SHCS HIV-positive individuals without ART (group B)
- HIV-1 RNA >1000 copies/ml (<3 months before baseline)
- CD4-cell count >500 cells/µl (<3 months before baseline)
- Participation in the SHCS Healthy HIV-negative volunteers (group C)
- Negative HIV-screening test (<3 months before baseline)
- CD4 cell count >500 cells/µl
Exclusion criteria: Common exclusion criteria
- Contraindications on ethical grounds
- Involvement in a conflicting (vaccine or investigational drug) clinical trial (except from the participation in the Swiss HIV Cohort Study).
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject.
- Pregnancy or breast feeding.
- Other clinically relevant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc),
- Known or suspected non-compliance, drug- or alcohol abuse.
Specific exclusion criteria
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01213810
University of Zurich
||Barbara Hasse, MD
||University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
||University of Zurich
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 13, 2010
||February 28, 2013
Keywords provided by University of Zurich:
VZV (Varicella zoster Virus)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on January 19, 2017
DNA Virus Infections
Physiological Effects of Drugs